Breast Cancer Trial, Recruiting NCT04671511 Sponsor: Jewish General Hospital Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT04671511
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older.
  • You have been diagnosed with a specific type of early-stage breast cancer (stage T1 or T2 invasive ductal or lobular), regardless of hormone receptor or HER2 status.
  • Your lymph nodes under the arm feel normal to the touch, and an ultrasound scan shows no more than two suspicious lymph nodes in that area.
  • A biopsy (tissue sample) has confirmed that cancer has spread to at least one lymph node under the arm.
  • You are generally able to carry out daily activities and care for yourself — your doctor will assess this using a standard performance scale (confirm with trial site).
  • You are willing and able to read, understand, and sign the consent form for the trial.

Who may not be able to join:

  • You have previously had surgery on the lymph nodes under the arm on the same side as the breast cancer, including a sentinel lymph node biopsy.
  • Your cancer has already spread to other parts of the body (distant metastases).
  • You have previously had radiotherapy treatment to the lymph nodes under the arm.
  • You have already received chemotherapy, hormone therapy, or other treatments before surgery (neoadjuvant therapy).
  • If a blue dye injection is planned as part of the procedure, you cannot join if you have a known allergy or sensitivity to certain blue dyes or similar substances used in the process (confirm with trial site).
  • You are unable to give your own informed consent to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jean-François Boileau, MD,MSc,FRCSC, Jewish General Hospital

Phone: 514-340-8222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Jewish General Hospital
Registry
ClinicalTrials.gov
Start date
30 March 2021
Est. completion
1 July 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Reduction in recommended completion node dissection rate (CND) with the use of Targeted Axillary Dissection (TAD) vs. Sentinel Node Biopsy (SNB) alone.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov